Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.55% is 12% below its 5-year average of -39.00%, near the high end of its 5-year range (-216.39%–0.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 172.97% below its 12-month average of -15.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.55%.
RETURN ON EQUITY (ROE)
-43.55%
RETURN ON EQUITY (ROE) AVG TTM
-15.95%
RETURN ON EQUITY (ROE) AVG 3Y
-32.70%
RETURN ON EQUITY (ROE) AVG 5Y
-39.00%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-172.97%
CURRENT VS 3Y AVG
-33.18%
CURRENT VS 5Y AVG
-11.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-3.66%
vs the sector median at left
GeneDx Holdings Corp.
Market Cap
$2.13B
Return on Equity (ROE)
-43.55%
TTM Avg
-15.95%
3Y Avg
-32.70%
5Y Avg
-39.00%
Market Cap
$2.11B
Return on Equity (ROE)
9.17%
TTM Avg
8.21%
3Y Avg
8.13%
5Y Avg
7.80%
Market Cap
$2.11B
Return on Equity (ROE)
-98.56%
TTM Avg
-37.96%
3Y Avg
-71.53%
5Y Avg
-45.53%
Market Cap
$2.11B
Return on Equity (ROE)
-23.58%
TTM Avg
-182.08%
3Y Avg
-186.85%
5Y Avg
-151.51%
Market Cap
$2.17B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
Market Cap
$2.17B
Return on Equity (ROE)
-57.96%
TTM Avg
-57.45%
3Y Avg
-48.08%
5Y Avg
-40.68%
Market Cap
$2.06B
Return on Equity (ROE)
-58.45%
TTM Avg
-43.81%
3Y Avg
-43.57%
5Y Avg
-51.47%
Market Cap
$2.06B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | $2.13B | -43.55% | -15.95% | -32.70% | -39.00% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -98.56% | -37.96% | -71.53% | -45.53% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -23.58% | -182.08% | -186.85% | -151.51% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.82% | -53.05% | -23.57% | 8.38% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -57.96% | -57.45% | -48.08% | -40.68% |
| Alvotech (ALVO)vs › | $2.08B | N/A | 23.18% | 49.13% | 48.50% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -58.45% | -43.81% | -43.57% | -51.47% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -42.07% | -35.11% | -34.40% | -30.49% |
| Vericel Corporation (VCEL)vs › | $2.05B | 6.55% | 4.11% | -0.47% | -0.69% |
ROE
-43.5%
ROA
-22.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.55% |
| 2026-03-31 | -30.62% |
| 2025-12-31 | -6.82% |
| 2025-09-30 | 0.71% |
| 2025-06-30 | 0.51% |
| 2025-03-31 | -14.99% |
| 2024-12-31 | -21.32% |
| 2024-09-30 | -40.83% |
| 2024-06-30 | -60.54% |
| 2024-03-31 | -65.16% |
| 2023-12-31 | -77.09% |
| 2023-09-30 | -180.43% |
| 2023-06-30 | -166.85% |
| 2023-03-31 | -162.29% |
| 2022-12-31 | -216.39% |
| 2022-09-30 | -50.00% |
| 2022-06-30 | -26.73% |
| 2022-03-31 | -39.69% |
| 2021-12-31 | -63.29% |
| 2021-09-30 | -84.57% |
